Efficacy of Levetiracetam and Phenobarbital as First-Line Treatment for Neonatal Seizures. (April 2022)

• Record Type: Journal Article
• Authors: Verwoerd, Carmen; Limjoco, Jamie; Rajamanickam, Victoria; Knox, Andrew
• Is Part Of: Journal of child neurology. Volume 37:Number 5(2022)
• Page Start: 401
• Page End: 409
• Publication Date: 2022-04
• Subjects: antiseizure medication -- electroencephalography -- levetiracetam -- neonate -- neonatal seizures; Nervous system -- Diseases -- Periodicals; 618.928
• DOI: 10.1177/08830738221086107
• Languages: English
• ISSNs: 0883-0738

Abstract

High neonatal seizure burden is associated with worsened neurodevelopmental outcomes. We compared the efficacy of initial treatment with levetiracetam vs phenobarbital for maintaining low seizure burden in a retrospective cohort of 25 neonates monitored with video electroencephalography (EEG). Video EEG tracing were reviewed and paired with medication bolus times to determine seizure burden after treatment. Initial cumulative dose of phenobarbital was 20 mg/kg in all but 1 case; initial cumulative dose of levetiracetam ranged from 50 to 100 mg/kg. Eleven of 17 (65%) patients sustained seizure burden <10% following initial treatment with levetiracetam, compared with 5 of 8 (63%) with phenobarbital. Thirteen (76%) patients treated with levetiracetam had sustained seizure burden <20% compared with 6 (75%) treated with phenobarbital. The phenobarbital group showed a larger absolute reduction in average seizure burden in the hour before and after treatment (−24.3 vs −14.2 minutes/h). Six of 17 (35%) patients treated with levetiracetam remained seizure free after initial treatment, compared with 2 of 8 (25%) patients treated with phenobarbital. Initial treatment with levetiracetam was associated with shorter average time to seizure freedom (15 vs 21 hours). None of these results were statistically significant. Cumulative doses of levetiracetam 100 mg/kg were well tolerated and associated with substantial decrease in seizure burden in several cases. Levetiracetam remains a promising first-line treatment for neonatal seizures; additional randomized controlled trials evaluating the effects of high-dose levetiracetam on seizure burden and long-term outcomes are warranted.